Literature DB >> 12388636

Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.

Elizabeth A Bolan1, Ronald J Tallarida, Gavril W Pasternak.   

Abstract

Pharmacological differences among mu opioid drugs have been observed in in vitro and in vivo preclinical models, as well as clinically, implying that all mu opioids may not be working through the same mechanism of action. Here we demonstrate analgesic synergy between L-methadone and several mu opioid ligands. Of the compounds examined, L-methadone selectively synergizes with morphine, morphine-6beta-glucuronide, codeine, and the active metabolite of heroin, 6-acetylmorphine. Morphine synergizes only with L-methadone. In analgesic assays, D-methadone was inactive alone and did not enhance morphine analgesia when the two were given together, confirming that L-methadone was not acting through N-methyl-D-aspartate mechanisms. Both L-methadone and morphine displayed only additive effects when paired with oxymorphone, oxycodone, fentanyl, alfentanyl, or meperidine. Although it displays synergy in analgesic assays, the L-methadone/morphine combination does not exhibit synergy in the gastrointestinal transit assay. This analgesic synergy of L-methadone with selective mu opioid drugs and the differences in opioid-mediated actions suggest that these drugs may be acting via different mechanisms. These findings provide further evidence for the complexity of the pharmacology of mu opioids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388636     DOI: 10.1124/jpet.102.035881

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  Recent advances in clinical use of opioids.

Authors:  Eric Chevlen
Journal:  Curr Pain Headache Rep       Date:  2004-06

2.  Synergism between fentanyl and tramadol in tonic inflammatory pain: the orofacial formalin test.

Authors:  Hugo F Miranda; Viviana Noriega; Ramiro J Zepeda; Fernando Sierralta; Juan C Prieto
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 3.  The determination and application of fixed-dose analgesic combinations for treating multimodal pain.

Authors:  Robert B Raffa; Joseph V Pergolizzi; Ronald J Tallarida
Journal:  J Pain       Date:  2010-03-24       Impact factor: 5.820

Review 4.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

5.  Promoting science in a pragmatic world: not (yet) time for partial opioid rotation.

Authors:  Florian Strasser
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 6.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

Review 7.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 8.  Preclinical pharmacology and opioid combinations.

Authors:  Gavril W Pasternak
Journal:  Pain Med       Date:  2012-03       Impact factor: 3.750

9.  The role of methadone in opioid rotation-a Polish experience.

Authors:  Wojciech Leppert
Journal:  Support Care Cancer       Date:  2008-11-29       Impact factor: 3.603

10.  Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions.

Authors:  Ying-Xian Pan; Jin Xu; Mingming Xu; Grace C Rossi; Joshua E Matulonis; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.